Designing better cancer therapies
Immuno-oncology is a promising new front on the fight against cancer. Exploiting the existence of tumor-specific antigens, immunotherapies aim to entrain the body’s immune system to specifically target and destroy cancer cells.
Systematic and reliable profiling of cytokine levels from minimally invasive biofluid samples affords valuable information about patient immune response, therapy progress, and key immune mechanisms that can be leveraged for novel or personalized treatments. LUNARIS™ Kits enable precise, multiplexed protein profiling that is being thoroughly tested in the context of immune-oncology applications, including risk assessment based on cytokine levels as prognostic markers in blood cancer treatment.
Because reconstitution of hematopoietic lineages is delayed in UCBT recipients, the clinical research team focused on cytokines which can be measured in patients’ plasma at any time point before or after UCBT. Testing of individual cytokine levels by standard methods, such as ELISA, requires significant sample volume, multiple separate assessments and is costly and time consuming.
Therefore, the clinical team chose to use the LUNARIS™ Human 11-Plex Cytokine Multiplex Protein Detection Method, which allows simultaneous assessment of multiple cytokines in a very small volume of the patient´s serum or plasma, to assess the prognostic value of this multi-cytokine profile in adult UCBT recipients.
Vassiliki A. Boussiotis MD, PhD, Hemato-Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA